

29

RABBIT ANTI-ALL SERUM: SPECIFICITY AND CLINICAL SIGNIFICANCE
 H. Kabisch, K. Winkler, H. Stührk, G. Landbeck,
 Abteilung für Blutgerinnungsforschung und Onkologie
 Universitäts-Kinderklinik Hamburg.
 The antiserum was produced according to a method published
 by GREAVES and coworkers. Cells reacting with the antiserum
 were labelled by indirect immunofluorescence. Blood, bone
 marrow and spinal fluid of different types of leukemia, other
 hematological disorders and infectious diseases were investi-
 gated. A significant positive reaction was observed only
 with ALL-cells of the PAS positive and the undifferentiated
 type. Leukemic cells of AML, ANML, AMOL, CLL, CML (adult and
 juvenile type), T-ALL as well as cells from Osteomyelofibro-
 sis, Osteomyeloclerosis, idiopathic thrombocytopenic purpura,
 Panmyelopathy and from infectious diseases did not show any
 significant reaction with the antiserum. In some doubtful
 cases this highly specific serum was helpful in establishing
 the diagnosis of ALL as well as assuring central nervous
 system disease or early bone-marrow-relapse.

32

**THE EFFECT OF HEMOLYZED RED BLOOD CELLS (RBC) ON NORMAL AND
 REGENERATING BONE MARROW.**

Rolf Lindemann.
 Department of Pediatrics, Rikshospitalet, Oslo 1, Norway.

Previous reports have demonstrated that RBC exert a nega-
 tive feedback on erythropoiesis (chalone principle). A sup-
 pression of one cell line would initiate the proliferation of
 the other cell lines originating from the pluripotent stem
 cell, i.e. competitive inhibition.

Hemolyzed RBC were used for inhibition of erythropoiesis.
 The studies were performed on normal mice and on mice with a
 regenerating bone marrow. The regenerating bone marrow was
 obtained by exposing the mice to 850 Rad followed by an i.v.
 injection of normal bone marrow cells. The mice were injected
 with the hemolyzed RBC for 4 to 7 days. There was no change
 in the total number of bone marrow cells, while a significant
 increase of the myelopoietic cells was observed.

In vitro studies indicated that the hemolyzed RBC acted
 on the committed erythroid stem cell (CFU-E), by inhibiting
 the transformation of the CFU-E into proerythroblasts. The
 number of CFU-C (myelopoietic colony forming unit) was not
 affected by the hemolyzed RBC.

It is suggested that patients with aplastic anemias or
 malignant blood diseases should be transfused with RBC in order
 to keep their Hb above 10 g/dl. The suppression of the erythro-
 poietic activity would by a competitive inhibition stimulate
 myelopoiesis and thrombopoiesis.

30

EFFECTS OF PHOSPHORUS ADMINISTRATION IN THALASSEMIA MAJOR
 A. KARAKLIS, P. LAPATSANIS, S. STAMOULAKATOU, S. DOXIADIS
 Institute of Child Health, Athens, Greece

Previous work has demonstrated marked phosphaturia in thalassaemia major,
 resulting in a negative phosphorus balance (Lapatsanis et al. Ped. 58:885,76).
 Therefore it was decided to study the effects of oral phosphate administration
 on serum phosphorus (Pi), red cell adenosine triphosphate (ATP) and 2,3-diphos-
 phoglycerate (2,3-DPG) in this disease. Group B of the table which was
 regularly transfused as was group A (control) received 1,5-2.0g of Pi as
 phosphate salt daily. p.o.

Groups	Nr	Hb* g%	Hct* ml%	Serum* Pi	R.C.* ATP	R.C.* 2,3-DPG
A	52	8.056	25.356	4.443	0.295	6.540
control		1.227	4.128	0.721	0.212	1.040
B	13	7.582	24.423	5.080	1.408	6.380
oral Pi		0.581	2.130	0.610	0.383	0.770

* Mean +/- SD.

Hemoglobin and hematocrit were not significantly different in the two
 groups. Serum Pi was significantly higher in group B compared to that of group
 A (p < 0.01). Mean red cell ATP was higher in group B from that of group A
 by 41%. The difference was highly significant (p < 0.001). On the contrary
 there was no difference in the mean red cell 2,3-DPG between the two groups.

The elevation of ATP was an expected and possibly beneficial finding.
 There is no explanation for the lack or response of 2,3-DPG to the raised
 serum Pi in group B. Since most of the red cells in these children were
 donor cells it indicates possibly an abnormality of blood bank blood in
 2,3-DPG metabolism.

33

**IMMUNOLOGICAL STUDY ON THE ACUTE LYMPHOBLASTIC LEUCEMIA OF CHILDREN
 (ALL)**

K. Mantalenaki-Lambrou, E. Vrachnou, S. Haidas, L. Zannos-Mariolea and
 N. Matsaniotis

First Department of Pediatrics of Athens University

Trial for immunological classification of ALL of children as well as
 for evaluation of the immune status during and after the ALL treatment
 was done.

We studied sixteen children aged two to twelve years old. T and B
 lymphocytes were measured (per cent and absolute number) of the
 peripheral blood.

Before any treatment the per cent of both T and B lymphocytes was
 very low. Most of the children had less than 15% T and 5% B lymphocytes
 respectively.

At the beginning of the induction therapy T and B lymphocytes (per
 cent and absolute numbers) were very low, but progressively they show
 an intention to increase.

During the reinduction periods, that lasted two years, T and B
 lymphocytes increased. After the radiation of the skull all the chil-
 dren showed a decrease of T lymphocytes.

We followed up two children for about two years after they had
 finished ALL treatment. Six months later they still had low numbers of
 T lymphocytes. At the end of the year their per cent and absolute num-
 bers of T lymphocytes had normal values that persisted for about 2 yrs.

31

**LYMPHOCYTE SENSITIZATION IN CHILDREN WITH LYMPHOBLASTIC LEUKEMIA AND
 LYMPHOMA AS MEASURED BY THE ELECTROPHORETIC MOBILITY TEST.**

F. Lampert*, U. Nitzschke, T. Zwergel
 Universitäts-Kinderpoliklinik, Giessen, W.-Germany.

A modified electrophoretic mobility (EM) test was performed in 53 children
 with lymphoblastic leukemia (ALL) and lymphoma to examine their lymphocyte
 sensitization to myelin basic protein (encephalitogenic factor). Measure-
 ments in the cytopherometer were facilitated by using devitalized sheep
 erythrocytes as indicator particles instead of macrophages.

A significant decrease in electrophoretic mobility as compared to an
 0-standard was found in 36 of 41 patients with ALL and in 12 of 12 patients
 with lymphoma; thus giving a sensitivity rate of 88 to 100%. Only 1 out of
 10 healthy individuals and 34 of 38 children with non-malignant disorders
 (autoimmune diseases excluded) also had a positive EM-test. Almost all
 patients with ALL were in hematological remission either on or off therapy.
 4 of the 5 non-reactive children with ALL were at diagnosis or in phase I
 of induction therapy. No striking change in lymphocyte reactivity was seen
 between lymphoblastic leukemia, Hodgkin's or Non-Hodgkin's lymphoma.

These results indicate that patients with lymphoid malignancies have
 remaining lymphocytes which had been sensitized by a common antigen of the
 malignant cell clone in the beginning of the disease.

* Supported by the Stiftung Volkswagenwerk

34

**LEUKAEMIC HYPOPION IN ACUTE LYMPHOBLASTIC LEUKAEMIA AFTER
 CESSATION OF THERAPY.**

G. Masera, V. Carnelli, C. Uderzo, C. Toselli
 Clinica Pediatrica, Università di Milano, Italy.

In acute lymphoblastic leukaemia antileukemic therapy is usually
 discontinued after 3-5 years of complete remission. It is,
 therefore, of particular interest to increase our knowledge of
 the subsequent course of events in these cases.

We present a girl of 7 years, affected with A.L.L. and treated
 with chemotherapy for 3 years. 4 months following the cessation
 of therapy she presented with photophobia, perikeratic
 injection of the left eye and copious exudate in the anterior
 chamber. Local therapy (cortisone - atropine) produced a brief
 remission. At the third recurrence of symptoms, cytological
 examination of the exudate revealed the presence of numerous
 lymphoblasts.

Radiotherapy produced a complete, lasting remission, still
 persisting after an interval of 5 months.

The eye can be considered a "Pharmacological Sanctuary",
 analogous with the C.N.S. and testis, and could be a
 possible site of localisation also in patients after completion
 of therapy.